Evaxion Biotech
Birgitte Rønø is the current Chief Scientific Officer at Evaxion Biotech. Prior to their current position, they worked as a Specialist for Diabetes Complication Research at Novo Nordisk from March 2013 to April 2017. During their time at Novo Nordisk, they were responsible for outlining, driving and implementing a pre-clinical strategy within the disease area. Additionally, they were a member of a cross-functional target innovation team and managed discovery projects. Some of their key achievements include project endorsement from top management and the implementation of a pre-clinical strategy for Diabetes Complication Research.
Birgitte Rønø has a PhD in Human Biology from Københavns Universitet - University of Copenhagen. Birgitte also has a Master of Science (MSc) in Human Biology from Københavns Universitet - University of Copenhagen.
Some of their coworkers include Jesper Nyegaard Nissen - COO, Jens Kringelum - Director, Genomic Immuno-Oncology, and Bo Karmark - CFO. Birgitte Rønø reports to Lars Wegner, CEO.
This person is not in any offices
Evaxion Biotech
7 followers
Evaxion is pioneering the field of immunoinformatics, working hard to bring novel, highly effective vaccines and antibodies to patients. By converting complex immunological data into computational algorithms, Evaxion is capable of programming the immune system to fight off a variety of diseases from cancers to hard-to-treat anti-microbial resistant infections.